Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01008150
Recruitment Status : Unknown
Verified October 2015 by NSABP Foundation Inc.
Recruitment status was:  Active, not recruiting
First Posted : November 5, 2009
Last Update Posted : October 6, 2015
Puma Biotechnology, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Actual Primary Completion Date : September 2015
  Estimated Study Completion Date : June 2017